Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDC 1421

Drug Profile

PDC 1421

Alternative Names: BLI-1005; PDC-1421

Latest Information Update: 23 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medical and Pharmaceutical Industry Technology and Development Center
  • Developer BioLite Inc
  • Class Antidepressants; Behavioural disorder therapies; Traditional Chinese medicine
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 01 Dec 2019 Phase-II clinical trials in Attention-deficit hyperactivity disorder in USA (PO) (NCT02699086)
  • 14 Nov 2019 Updated efficacy data from a phase-II trial in Major depressive disorder released by American BriVision
  • 14 Nov 2019 American BriVision plans pivotal phase III trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top